BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19490960)

  • 1. Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation.
    Pannaraj PS; Edwards MS; Ewing KT; Lewis AL; Rench MA; Baker CJ
    Vaccine; 2009 Jul; 27(33):4452-6. PubMed ID: 19490960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
    J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.
    Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Edwards MS; Kasper DL
    J Infect Dis; 2004 Mar; 189(6):1103-12. PubMed ID: 14999615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.
    Yang HH; Madoff LC; Guttormsen HK; Liu YD; Paoletti LC
    Infect Immun; 2007 Jul; 75(7):3455-61. PubMed ID: 17470542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
    Hillier SL; Ferrieri P; Edwards MS; Ewell M; Ferris D; Fine P; Carey V; Meyn L; Hoagland D; Kasper DL; Paoletti LC; Hill H; Baker CJ
    Clin Infect Dis; 2019 May; 68(12):2079-2086. PubMed ID: 30281066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.
    Yang HH; Mascuch SJ; Madoff LC; Paoletti LC
    Clin Vaccine Immunol; 2008 Jul; 15(7):1035-41. PubMed ID: 18463225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
    Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
    Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
    Baker CJ; Rench MA; Fernandez M; Paoletti LC; Kasper DL; Edwards MS
    J Infect Dis; 2003 Jul; 188(1):66-73. PubMed ID: 12825173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
    Paoletti LC; Rench MA; Kasper DL; Molrine D; Ambrosino D; Baker CJ
    Infect Immun; 2001 Nov; 69(11):6696-701. PubMed ID: 11598040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.
    Palazzi DL; Rench MA; Edwards MS; Baker CJ
    J Infect Dis; 2004 Aug; 190(3):558-64. PubMed ID: 15243932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X; LagergÄrd T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
    Baker CJ; Rench MA; Paoletti LC; Edwards MS
    Vaccine; 2007 Jan; 25(1):55-63. PubMed ID: 16919857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women.
    Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Carey VJ; Hickman ME; Kasper DL
    J Infect Dis; 2000 Oct; 182(4):1129-38. PubMed ID: 10979909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
    Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
    Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.
    Goyette-Desjardins G; Calzas C; Shiao TC; Neubauer A; Kempker J; Roy R; Gottschalk M; Segura M
    Infect Immun; 2016 Jul; 84(7):2059-2075. PubMed ID: 27113360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines.
    Edwards MS; Lane HJ; Hillier SL; Rench MA; Baker CJ
    Vaccine; 2012 Jun; 30(28):4123-6. PubMed ID: 22537994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines.
    Fattom AI; Sarwar J; Basham L; Ennifar S; Naso R
    Infect Immun; 1998 Oct; 66(10):4588-92. PubMed ID: 9746554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
    J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice.
    Paoletti LC; Pinel J; Rodewald AK; Kasper DL
    J Infect Dis; 1997 May; 175(5):1237-9. PubMed ID: 9129094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention.
    Palmeiro JK; De Carvalho NS; Botelho AC; Fracalanzza SE; Madeira HM; Dalla-Costa LM
    Vaccine; 2011 May; 29(21):3729-30. PubMed ID: 21414381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.